vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and SuperCom Ltd (SPCB). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $14.2M, roughly 1.3× SuperCom Ltd). SuperCom Ltd runs the higher net margin — 37.5% vs -90.7%, a 128.2% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -1.5%). SuperCom Ltd produced more free cash flow last quarter ($-3.6M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
Super.com is a technology company headquartered in San Francisco and co-founded by Hussein Fazal and Henry Shi. The company provides financial services, including reward programs and travel bookings.
NAMS vs SPCB — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $14.2M |
| Net Profit | $-17.4M | $5.3M |
| Gross Margin | — | 61.2% |
| Operating Margin | -186.1% | 16.3% |
| Net Margin | -90.7% | 37.5% |
| Revenue YoY | 740.1% | -1.5% |
| Net Profit YoY | 55.5% | 79.5% |
| EPS (diluted) | $-0.15 | $1.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $19.1M | $14.2M | ||
| Q4 24 | $12.8M | — | ||
| Q3 24 | $29.1M | — | ||
| Q2 24 | — | $14.4M | ||
| Q2 23 | $8.6M | $14.1M | ||
| Q2 22 | — | $6.3M |
| Q2 25 | $-17.4M | $5.3M | ||
| Q4 24 | $-92.2M | — | ||
| Q3 24 | $-16.6M | — | ||
| Q2 24 | — | $3.0M | ||
| Q2 23 | $-42.0M | $-2.6M | ||
| Q2 22 | — | $-5.2M |
| Q2 25 | — | 61.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 52.3% | ||
| Q2 23 | — | 27.2% | ||
| Q2 22 | — | 41.8% |
| Q2 25 | -186.1% | 16.3% | ||
| Q4 24 | -338.5% | — | ||
| Q3 24 | -85.9% | — | ||
| Q2 24 | — | 7.7% | ||
| Q2 23 | -461.8% | -12.2% | ||
| Q2 22 | — | -49.9% |
| Q2 25 | -90.7% | 37.5% | ||
| Q4 24 | -721.7% | — | ||
| Q3 24 | -57.2% | — | ||
| Q2 24 | — | 20.6% | ||
| Q2 23 | -486.9% | -18.3% | ||
| Q2 22 | — | -82.4% |
| Q2 25 | $-0.15 | $1.32 | ||
| Q4 24 | $-0.91 | — | ||
| Q3 24 | $-0.18 | — | ||
| Q2 24 | — | $1.19 | ||
| Q2 23 | $-0.51 | $-10.66 | ||
| Q2 22 | — | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $15.0M |
| Total DebtLower is stronger | — | $23.6M |
| Stockholders' EquityBook value | $778.5M | $37.3M |
| Total Assets | $815.1M | $65.5M |
| Debt / EquityLower = less leverage | — | 0.63× |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $739.2M | $15.0M | ||
| Q4 24 | $834.2M | — | ||
| Q3 24 | $422.7M | — | ||
| Q2 24 | — | $5.7M | ||
| Q2 23 | — | $1.1M | ||
| Q2 22 | — | $2.9M |
| Q2 25 | — | $23.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $29.2M | ||
| Q2 23 | — | $32.9M | ||
| Q2 22 | — | $32.3M |
| Q2 25 | $778.5M | $37.3M | ||
| Q4 24 | $757.5M | — | ||
| Q3 24 | $378.9M | — | ||
| Q2 24 | — | $13.8M | ||
| Q2 23 | $398.4M | $3.5M | ||
| Q2 22 | — | $3.7M |
| Q2 25 | $815.1M | $65.5M | ||
| Q4 24 | $864.6M | — | ||
| Q3 24 | $439.2M | — | ||
| Q2 24 | — | $49.6M | ||
| Q2 23 | — | $40.8M | ||
| Q2 22 | — | $42.7M |
| Q2 25 | — | 0.63× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.11× | ||
| Q2 23 | — | 9.49× | ||
| Q2 22 | — | 8.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $-2.2M |
| Free Cash FlowOCF − Capex | $-37.8M | $-3.6M |
| FCF MarginFCF / Revenue | -197.2% | -25.3% |
| Capex IntensityCapex / Revenue | 0.5% | 10.0% |
| Cash ConversionOCF / Net Profit | — | -0.41× |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | $-14.0M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-37.7M | $-2.2M | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.5M | — | ||
| Q2 24 | — | $-950.0K | ||
| Q2 23 | $-31.9M | $-3.4M | ||
| Q2 22 | — | $-4.1M |
| Q2 25 | $-37.8M | $-3.6M | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.6M | — | ||
| Q2 24 | — | $-1.6M | ||
| Q2 23 | $-31.9M | $-4.5M | ||
| Q2 22 | — | $-4.4M |
| Q2 25 | -197.2% | -25.3% | ||
| Q4 24 | -293.5% | — | ||
| Q3 24 | -43.2% | — | ||
| Q2 24 | — | -10.8% | ||
| Q2 23 | -369.3% | -31.5% | ||
| Q2 22 | — | -70.4% |
| Q2 25 | 0.5% | 10.0% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | — | 4.2% | ||
| Q2 23 | 0.1% | 7.4% | ||
| Q2 22 | — | 4.4% |
| Q2 25 | — | -0.41× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.32× | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
